PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för rezafungin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

25 hits

Bibliografisk träff 2024-08-01

Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults.

Smith HL, Bensman TJ, Mishra S, Li X, Dixon CA, Sheikh J, McMaster OG, Joshi A, Rubin DB, Goodwin A, Miller TJ, Danielsen ZY, Syed I, Shukla SJ, Iarikov D, Kim PW, Farley JJ.

J Infect Dis · journal article · DOI 10.1093/infdis/jiae146

Bibliografisk träff 2024-03-25

Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.

Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, Andrzejewski C, Bartizal K, Das AF, Sandison T, Thompson GR, Pappas PG.

Antimicrob Agents Chemother · clinical trial, phase iii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01584-23

Bibliografisk träff 2024-03-22

An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis.

Sharma D, Vazquez JA.

Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2024.2331775

Bibliografisk träff 2024-03-12

Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report.

Mori G, Gottardi M, Guffanti M, Castagna A, Lanzafame M.

JAC Antimicrob Resist · letter; journal article · DOI 10.1093/jacamr/dlae042

Bibliografisk träff 2024-03-09

New treatment options for critically important WHO fungal priority pathogens.

Kriegl L, Egger M, Boyer J, Hoenigl M, Krause R.

Clin Microbiol Infect · review; journal article · DOI 10.1016/j.cmi.2024.03.006

Bibliografisk träff 2024-01-18

Reshaping Echinocandin Antifungal Drugs To Circumvent Glucan Synthase Point-Mutation-Mediated Resistance.

Jospe-Kaufman M, Ben-Zeev E, Mottola A, Dukhovny A, Berman J, Carmeli S, Fridman M.

Angew Chem Int Ed Engl · research support, non-u.s. gov't; journal article · DOI 10.1002/anie.202314728

Bibliografisk träff 2023-11-28

Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.

Roepcke S, Passarell J, Walker H, Flanagan S.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00916-23

Bibliografisk träff 2023-11-23

New antifungals development: rezafungin in candidiasis treatment.

Desnos-Ollivier M, Lanternier F.

Lancet Infect Dis · comment; journal article · DOI 10.1016/s1473-3099(23)00627-8

Bibliografisk träff 2023-11-23

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.

Thompson GR, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, Kullberg BJ, Pullman J, Hites M, Fortún J, Horcajada JP, Kotanidou A, Das AF, Sandison T, Aram JA, Vazquez JA, Pappas PG.

Lancet Infect Dis · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1473-3099(23)00551-0

Bibliografisk träff 2023-07-20

The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.

Ordaya EE, Clement J, Vergidis P.

Mycopathologia · review-article; review; journal article · DOI 10.1007/s11046-023-00759-5

Bibliografisk träff 2023-07-01

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin.

Oliva A, De Rosa FG, Mikulska M, Pea F, Sanguinetti M, Tascini C, Venditti M.

Expert Rev Anti Infect Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1080/14787210.2023.2240956

Bibliografisk träff 2023-06-19

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis.

Jeck J, Jakobs F, Kurte MS, Cornely OA, Kron F.

JAC Antimicrob Resist · research-article; journal article · DOI 10.1093/jacamr/dlad079

Bibliografisk träff 2023-06-06

Novel Antifungals and Aspergillus Section Terrei with Potpourri Susceptibility Profiles to Conventional Antifungals.

Vahedi-Shahandashti R, Houbraken J, Birch M, Lass-Flörl C.

J Fungi (Basel) · research-article; journal article · DOI 10.3390/jof9060649

Bibliografisk träff 2023-06-01

Rezafungin: First Approval.

Syed YY.

Drugs · review; journal article · DOI 10.1007/s40265-023-01891-8

Bibliografisk träff 2023-05-29

Successful Rezafungin Treatment of an Azole-Resistant Chronic Mucocutaneous Candidiasis in a STAT-1 Gain-of-Function Patient.

Melenotte C, Ratiney R, Hermine O, Bougnoux ME, Lanternier F.

J Clin Immunol · letter; research support, non-u.s. gov't · DOI 10.1007/s10875-023-01519-2

Bibliografisk träff 2023-05-15

Rezafungin

Författaruppgift saknas

Journal missing · review

Bibliografisk träff 2023-05-08

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.

Flanagan S, Walker H, Ong V, Sandison T.

Microbiol Spectr · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/spectrum.01339-23

Bibliografisk träff 2023-04-01

Development and preliminary validation of a modified EUCAST yeast broth microdilution MIC method with Tween 20-supplemented medium for rezafungin.

Zuill DE, Almaguer AL, Donatelli J, Arendrup MC, Locke JB.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkad055

Bibliografisk träff 2023-02-22

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.

Lamoth F.

Infect Drug Resist · review-article; review; journal article · DOI 10.2147/idr.s375625

Bibliografisk träff 2022-11-25

Rezafungin and invasive candida infections: a new game changing antifungal?

Guinea J.

Lancet · comment; journal article · DOI 10.1016/s0140-6736(22)02371-6

Bibliografisk träff 2022-11-25

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.

Thompson GR, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG, ReSTORE trial investigators.

Lancet · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(22)02324-8

Bibliografisk träff 2022-10-01

Aneuploidy underlies paradoxical growth of rezafungin and enables cross-tolerance to echinocandins in Candida albicans.

Li H, Cao YB, Yan TH, Jiang YY, Yang F.

J Infect · letter; research support, non-u.s. gov't · DOI 10.1016/j.jinf.2022.09.028

Bibliografisk träff 2022-07-18

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.

Carvalhaes CG, Rhomberg PR, Pfaller MA, Locke JB, Castanheira M.

Mycoses · journal article · DOI 10.1111/myc.13490

Bibliografisk träff 2022-05-04

A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.

Gu K, Ruff D, Key C, Thompson M, Jiang S, Sandison T, Flanagan S.

Clin Transl Sci · brief-report; clinical trial, phase i; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1111/cts.13286

Bibliografisk träff 2022-03-07

Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).

Carvalhaes CG, Klauer AL, Rhomberg PR, Pfaller MA, Castanheira M.

J Clin Microbiol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/jcm.02449-21

Go to research.

Publications in the selection

Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults.

Outcomes by <i>Candida</i> spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.

An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis.

Treatment of <i>Candida glabrata</i> native valve endocarditis with rezafungin: a case report.

New treatment options for critically important WHO fungal priority pathogens.

Reshaping Echinocandin Antifungal Drugs To Circumvent Glucan Synthase Point-Mutation-Mediated Resistance.

Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.

New antifungals development: rezafungin in candidiasis treatment.

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.

The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.

Invasive <i>Candida</i> infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin.

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis.

Novel Antifungals and <i>Aspergillus</i> Section <i>Terrei</i> with Potpourri Susceptibility Profiles to Conventional Antifungals.

Rezafungin: First Approval.

Successful Rezafungin Treatment of an Azole-Resistant Chronic Mucocutaneous Candidiasis in a STAT-1 Gain-of-Function Patient.

Rezafungin

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.

Development and preliminary validation of a modified EUCAST yeast broth microdilution MIC method with Tween 20-supplemented medium for rezafungin.

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.

Rezafungin and invasive candida infections: a new game changing antifungal?

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.

Aneuploidy underlies paradoxical growth of rezafungin and enables cross-tolerance to echinocandins in Candida albicans.

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.

A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.

Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).